Although knock-down of PARP1 in osteosarcoma cells in vitro reduced cellular growth and enhanced apoptosis as well as susceptibility to chemotherapy [102], the PARP1 inhibitor talazoparib did not show any significant clinical activity in a recent trial [76]. Here, PARP1 is linked to osteosarcoma.